An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
A phase 2 trial of Cadonilimab, Ivonescimab in ovarian cancer, run by Akeso, now recruiting.
Overview
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT06560112 by Akeso, with 172 participants planned, started 2024-11-12 and due to reach its primary completion in 2026-05-01. Interventions recorded: AK104, AK112, Chemotherapy. Conditions listed: Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialCombination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
Shares Ivonescimab, Akeso, Ovarian cancer.
- TrialA Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialAK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialA Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Shares Cadonilimab, Ivonescimab, Akeso.
- TrialA Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Shares Cadonilimab, Akeso.
- TrialA Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Shares Cadonilimab, Akeso.
- TrialA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor
Shares Ivonescimab, Akeso.
- TrialA Study of Ivonescimab in First-Line ES-SCLC
Shares Cadonilimab, Ivonescimab, Akeso.